$1.56 Million in Sales Expected for Neurocrine Biosciences, Inc. (NBIX) This Quarter
Analysts forecast that Neurocrine Biosciences, Inc. (NASDAQ:NBIX) will announce sales of $1.56 million for the current fiscal quarter, according to Zacks Investment Research. Two analysts have made estimates for Neurocrine Biosciences’ earnings, with the highest sales estimate coming in at $2.12 million and the lowest estimate coming in at $1.00 million. The firm is expected to issue its next earnings report on Wednesday, August 2nd.
On average, analysts expect that Neurocrine Biosciences will report full year sales of $1.56 million for the current financial year, with estimates ranging from $35.72 million to $51.80 million. For the next financial year, analysts expect that the firm will report sales of $169.31 million per share, with estimates ranging from $121.49 million to $227.57 million. Zacks Investment Research’s sales averages are an average based on a survey of sell-side research analysts that follow Neurocrine Biosciences.
Neurocrine Biosciences (NASDAQ:NBIX) last released its quarterly earnings results on Tuesday, May 9th. The company reported ($0.90) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.67) by $0.23. During the same period last year, the firm posted ($0.22) earnings per share.
A number of research firms have commented on NBIX. Oppenheimer Holdings, Inc. reissued an “outperform” rating and issued a $70.00 price target on shares of Neurocrine Biosciences in a research note on Wednesday, July 5th. BidaskClub raised shares of Neurocrine Biosciences from a “sell” rating to a “hold” rating in a research note on Wednesday, June 21st. ValuEngine raised shares of Neurocrine Biosciences from a “strong sell” rating to a “sell” rating in a research note on Friday, June 2nd. Jefferies Group LLC reissued a “buy” rating and issued a $66.00 price target on shares of Neurocrine Biosciences in a research note on Tuesday, May 30th. Finally, Piper Jaffray Companies set a $68.00 price target on shares of Neurocrine Biosciences and gave the stock a “buy” rating in a research note on Wednesday, May 24th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and sixteen have given a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus price target of $67.69.
Neurocrine Biosciences (NASDAQ:NBIX) traded down 1.51% during trading on Friday, hitting $47.07. The stock had a trading volume of 1,019,815 shares. Neurocrine Biosciences has a one year low of $37.35 and a one year high of $55.38. The firm’s market cap is $4.15 billion. The stock’s 50-day moving average is $45.94 and its 200 day moving average is $45.82.
In related news, insider Malcolm Lloyd-Smith sold 9,960 shares of the company’s stock in a transaction on Friday, May 19th. The shares were sold at an average price of $53.63, for a total transaction of $534,154.80. Following the completion of the sale, the insider now directly owns 17,997 shares in the company, valued at approximately $965,179.11. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Corinne H. Nevinny sold 5,000 shares of the company’s stock in a transaction on Friday, May 5th. The shares were sold at an average price of $53.98, for a total transaction of $269,900.00. Following the sale, the director now owns 34,603 shares of the company’s stock, valued at $1,867,869.94. The disclosure for this sale can be found here. Insiders sold a total of 71,699 shares of company stock valued at $3,855,122 in the last ninety days. 4.80% of the stock is owned by corporate insiders.
A number of large investors have recently bought and sold shares of NBIX. First Mercantile Trust Co. raised its stake in Neurocrine Biosciences by 22.2% in the first quarter. First Mercantile Trust Co. now owns 3,082 shares of the company’s stock worth $133,000 after buying an additional 560 shares in the last quarter. Independent Portfolio Consultants Inc. purchased a new stake in Neurocrine Biosciences during the first quarter worth approximately $106,000. Nationwide Fund Advisors raised its stake in Neurocrine Biosciences by 20.9% in the first quarter. Nationwide Fund Advisors now owns 126,631 shares of the company’s stock worth $5,483,000 after buying an additional 21,922 shares in the last quarter. Candriam Luxembourg S.C.A. raised its stake in Neurocrine Biosciences by 46.2% in the first quarter. Candriam Luxembourg S.C.A. now owns 247,000 shares of the company’s stock worth $10,696,000 after buying an additional 78,000 shares in the last quarter. Finally, Columbus Circle Investors raised its stake in Neurocrine Biosciences by 33.3% in the first quarter. Columbus Circle Investors now owns 207,699 shares of the company’s stock worth $8,993,000 after buying an additional 51,872 shares in the last quarter. Institutional investors own 95.74% of the company’s stock.
COPYRIGHT VIOLATION WARNING: This piece was first posted by American Banking News and is the sole property of of American Banking News. If you are reading this piece on another website, it was stolen and reposted in violation of United States & international trademark and copyright law. The legal version of this piece can be accessed at https://www.americanbankingnews.com/2017/07/22/1-56-million-in-sales-expected-for-neurocrine-biosciences-inc-nbix-this-quarter.html.
Neurocrine Biosciences Company Profile
Neurocrine Biosciences, Inc is engaged in discovering and developing pharmaceuticals, in diseases with unmet medical needs, through its research and development (R&D) platform, focused on neurological and endocrine based diseases and disorders. Its three lead late-stage clinical programs are elagolix, which is a gonadotropin-releasing hormone (GnRH) antagonist for endometriosis and uterine fibroids; INGREZZA (valbenazine), which is a vesicular monoamine transporter 2 (VMAT2) inhibitor, for the treatment of movement disorders, and opicapone, which is a selective catechol-O-methyltransferase inhibitor that is an adjunct therapy to preparations of levodopa/Dihydroxyphenylalanine (DOPA) decarboxylase inhibitors for adult patients with Parkinson’s disease.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Neurocrine Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.